SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Fresenius Medical Care AG & Co. KGAA, and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)-- Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Fresenius Medical Care AG & Co. KGAA, (“Fresenius” or the “Company”) (NYSE: FMS) concerning possible violations of federal securities laws.

To get more information about this investigation, click here, or please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at [email protected].

Fresenius is a kidney dialysis company that offers dialysis treatment and other dialysis care services, as well as different health services. On January 7, 2017, Fresenius announced that it was subpoenaed by federal prosecutors due to the Company’s interactions with the American Kidney Fund, an American charity providing financial aid for kidney dialysis patients.

When this information was released to the public, the value of Fresenius stock fell severely, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170126006396/en/

Lundin Law PC
Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

[email protected]

http://lundinlawpc.com/

Source: Lundin Law PC